a de la companya de l	OF THORACIC	
	TOP THORAGE	<b>JACCEDONUS</b>
(.	A Ŷ	.)
	Established 1964	
<b>T</b> -	L.L.	4

## STS Congenital Heart Surgery Data Summary Neonates

U Duke Clinical Research Institute

## STS Period Ending 12/31/2017 Table 1: Neonates number submitted, in analysis, and operative mortality

	ST	STS		
	Last 1 Year Jan 2017 - Dec 2017	Last Four Years Jan 2014 - Dec 2017		
Number of Operations/Patiente				
Number of Operations/Patients	0.000	20 572		
Operations in Analysis <sup>1</sup> Patients in Analysis <sup>2</sup>	6,886	29,572		
Patients in Analysis <sup>2</sup>	4,723	20,351		
Operative Mortality <sup>3</sup>				
Number of Mortalities	309	1,463		
		17,403		
Number Eligible	4,153	17,540		
Mortality Percent Mortality (95% CI)	7.4%	8.3%		
Mortality (95% CI)	(6.7 , 8.3)	(7.9 , 8.8)		
14 seturis instudes anti-mentions descripted as #ODD# as #NE ODD. Conditions				

<sup>1</sup>Analysis includes only operations classified as "CPB" or "No CPB, Cardiovascular"

<sup>2</sup>Patient Numbers represent distinct patient admissions

<sup>3</sup>Mortality numbers are patient-based only for admission in the analysis population at sites with adequate mortality data



## STS Congenital Heart Surgery Data Summary Neonates

U Duke Clinical Research Institute

STS Period Ending 12/31/2017

## Table 2: Primary diagnosis, 35 Most Frequent for Neonates, Last 4 Years (Jan 2014 - Dec 2017)

STS
N % of All
4,077 13.8%
3,254 11.0%
2,615 8.8%
2,148 7.3%
1,917 6.5%
1,059 3.6%
812 2.7%
724 2.4%
687 2.3%
650 2.2%
638 2.2%
585 2.0%
555 1.9%
504 1.7%
486 1.6%
479 1.6%
466 1.6%
452 1.5%
395 1.3%
390 1.3%
377 1.3%
360 1.2%
318 1.1%
282 1.0%
257 0.9%
252 0.9%
242 0.8%
209 0.7%
185 0.6%
181 0.6%
176 0.6%
173 0.6%
155 0.5%
150 0.5%
142 0.5%
155 150

STS Congenital Heart Surgery Data Summary Neonates STS Period Ending 12/31/2017		<b>U Duke</b> Cl	<b>Unite Clinical Research Institute</b>			
Table 3: Primary procedure, 35 Most Frequent for Neonates, Last 4 Years (Jan 2014 - Dec 2017)						
	STS					
Primary Procedure	N	% of All	% Mort.			
Delayed sternal closure	5,665	21.4%	0.1%			
Norwood procedure	2,708	10.2%	14.4%			
Arterial switch operation (ASO)	1,835	6.9%	2.0%			
Mediastinal exploration	1,683	6.4%	0.4%			
Shunt, Systemic to pulmonary, Modified Blalock-Taussig Shunt (MBTS)	1,570	5.9%	6.7%			
Coarctation repair, End to end, Extended	1,470	5.6%	1.6%			
PA banding (PAB)	1,362	5.1%	8.8%			
TAPVC repair	1,201	4.5%	7.0%			
Aortic arch repair	1,094	4.1%	3.4%			
Arterial switch operation (ASO) and VSD repair	667	2.5%	4.5%			
Aortic arch repair + VSD repair	655	2.5%	2.3%			
Shunt, Systemic to pulmonary, Central (shunt from aorta)	599	2.3%	8.2%			
Truncus arteriosus repair	502	1.9%	9.6%			
Interrupted aortic arch repair	460	1.7%	3.3%			
Coarctation repair, End to end	319	1.2%	3.1%			
Arterial switch procedure and VSD repair + Aortic arch repair	298	1.1%	14.8%			
Hybrid Approach Stage 1, Stent placement in arterial duct (PDA) + application of RPA & LPA bands	296	1.1%	18.6%			
Hybrid Approach Stage 1, Application of RPA & LPA bands	236	0.9%	36.9%			
TOF repair, Ventriculotomy, Transanular patch	217	0.8%	2.8%			
PDA closure, Surgical	212	0.8%	6.1%			
Sternotomy wound drainage	145	0.5%	0.0%			
Conduit placement, RV to PA	117	0.4%	9.4%			
VSD repair, Patch	114	0.4%	0.9%			
Mediastinal procedure	112	0.4%	1.8%			
PA, reconstruction (plasty), Branch, Central (within the hilar bifurcation)	109	0.4%	2.8%			
Shunt, Reoperation	109	0.4%	0.0%			
Pericardial drainage procedure	105	0.4%	3.8%			
Coarctation repair + VSD repair	103	0.4%	3.9%			
Pulmonary atresia - VSD (including TOF, PA) repair	102	0.4%	3.9%			
Vascular ring repair	100	0.4%	1.0%			
TAPVC repair + Shunt - systemic-to-pulmonary	97	0.4%	41.2%			
Coarctation repair, Subclavian flap	94	0.4%	2.1%			
RVOT procedure	91	0.3%	11.0%			
TOF repair, RV-PA conduit	86	0.3%	9.3%			
Coarctation repair, Patch aortoplasty	83	0.3%	3.6%			